These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 289861)

  • 1. Structural features of angiotensin II which are important for biologic activity.
    Peach MJ
    Kidney Int Suppl; 1979 Mar; (9):S3-6. PubMed ID: 289861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Novel cyclic analogs of angiotensin II with cyclization between positions 5 and 7: conformational and biological implications.
    Zhang WJ; Nikiforovich GV; Pérodin J; Richard DE; Escher E; Marshall GR
    J Med Chem; 1996 Jul; 39(14):2738-44. PubMed ID: 8709104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Three-dimensional recognition requirements for angiotensin agonists: a novel solution for an old problem.
    Nikiforovich GV; Marshall GR
    Biochem Biophys Res Commun; 1993 Aug; 195(1):222-8. PubMed ID: 8363604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis and AT2 receptor-binding properties of angiotensin II analogues.
    Rosenström U; Sköld C; Lindeberg G; Botros M; Nyberg F; Hallberg A; Karlén A
    J Pept Res; 2004 Nov; 64(5):194-201. PubMed ID: 15485557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. On the molecular basis of the recognition of angiotensin II (AII). NMR structure of AII in solution compared with the X-ray structure of AII bound to the mAb Fab131.
    Tzakos AG; Bonvin AM; Troganis A; Cordopatis P; Amzel ML; Gerothanassis IP; van Nuland NA
    Eur J Biochem; 2003 Mar; 270(5):849-60. PubMed ID: 12603318
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Conformational analysis of two cyclic analogs of angiotensin: implications for the biologically active conformation.
    Nikiforovich GV; Kao JL; Plucinska K; Zhang WJ; Marshall GR
    Biochemistry; 1994 Mar; 33(12):3591-8. PubMed ID: 8142357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Studies defining minimal receptor domains for angiotensin II.
    Pendleton RG; Gessner G; Horner E
    J Pharmacol Exp Ther; 1989 Jul; 250(1):31-6. PubMed ID: 2746504
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the His273 located in the sixth transmembrane domain of the angiotensin II receptor subtype AT2 in ligand-receptor interaction.
    Turner CA; Cooper S; Pulakat L
    Biochem Biophys Res Commun; 1999 Apr; 257(3):704-7. PubMed ID: 10208847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The design and synthesis of a potent Angiotensin II cyclic analogue confirms the ring cluster receptor conformation of the hormone Angiotensin II.
    Matsoukas JM; Polevaya L; Ancans J; Mavromoustakos T; Kolocouris A; Roumelioti P; Vlahakos DV; Yamdagni R; Wu Q; Moore GJ
    Bioorg Med Chem; 2000 Jan; 8(1):1-10. PubMed ID: 10968258
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin antagonists and the adrenal cortex and medulla.
    Peach MJ; Ackerly JA
    Fed Proc; 1976 Nov; 35(13):2502-7. PubMed ID: 976492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Angiotensin II analogues. 13. Role of the hydroxyl group of position 4 tyrosine in pressor activity.
    Hsieh K; Kiraly-Olah IC; Jorgensen EC; Lee TC
    J Med Chem; 1979 Sep; 22(9):1051-55. PubMed ID: 490549
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The angiotensin II AT1 receptor structure-activity correlations in the light of rhodopsin structure.
    Oliveira L; Costa-Neto CM; Nakaie CR; Schreier S; Shimuta SI; Paiva AC
    Physiol Rev; 2007 Apr; 87(2):565-92. PubMed ID: 17429042
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Current problems of active substance research. 3. Structure-activity relationships of angiotensin II and analog].
    Piesche L; Hilse H; Scheer E
    Pharmazie; 1974 Apr; 29(4):233-51. PubMed ID: 4152658
    [No Abstract]   [Full Text] [Related]  

  • 14. In vitro degradation of angiotensin II (A-II) by human placental subcellular fractions, pregnancy sera and purified placental aminopeptidases.
    Mizutani S; Akiyama H; Kurauchi O; Taira H; Narita O; Tomoda Y
    Acta Endocrinol (Copenh); 1985 Sep; 110(1):135-9. PubMed ID: 3898693
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A selective AT2 receptor ligand with a gamma-turn-like mimetic replacing the amino acid residues 4-5 of angiotensin II.
    Rosenström U; Sköld C; Lindeberg G; Botros M; Nyberg F; Karlén A; Hallberg A
    J Med Chem; 2004 Feb; 47(4):859-70. PubMed ID: 14761188
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of the substitution of Phe4 in the opioid peptide [D-Ala8]dynorphin A-(1-11)NH2.
    Vig BS; Zheng MQ; Murray TF; Aldrich JV
    J Med Chem; 2003 Sep; 46(19):4002-8. PubMed ID: 12954053
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Structural comparison between type I and type II antagonists: possible implications in the drug design of AT1 antagonists.
    Roumelioti P; Tselios T; Alexopoulos K; Mavromoustakos T; Kolocouris A; Moore GJ; Matsoukas JM
    Bioorg Med Chem Lett; 2000 Apr; 10(8):755-8. PubMed ID: 10782679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Elucidation of a specific binding site for angiotensin II(3-8), angiotensin IV, in mammalian heart membranes.
    Hanesworth JM; Sardinia MF; Krebs LT; Hall KL; Harding JW
    J Pharmacol Exp Ther; 1993 Aug; 266(2):1036-42. PubMed ID: 8355180
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A novel class of orally active non-peptide bradykinin B2 receptor antagonists. 1. Construction of the basic framework.
    Abe Y; Kayakiri H; Satoh S; Inoue T; Sawada Y; Imai K; Inamura N; Asano M; Hatori C; Katayama A; Oku T; Tanaka H
    J Med Chem; 1998 Feb; 41(4):564-78. PubMed ID: 9484506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On the structural basis of the hypertensive properties of angiotensin II: a solved mystery or a controversial issue?
    Tzakos AG; Gerothanassis IP; Troganis AN
    Curr Top Med Chem; 2004; 4(4):431-44. PubMed ID: 14965310
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.